Inflammatory response in epidermal tissue

The term "Inflammatory response in epidermal tissue" does not refer to a single molecular target but rather describes a complex biological process involving multiple cell types (keratinocytes, neutrophils, macrophages), soluble mediators (cytokines, chemokines), extracellular matrix components, and signaling pathways. This process is initiated by tissue injury or infection and involves vasodilation, increased vascular permeability, immune cell recruitment via chemotaxis and diapedesis, pathogen clearance through phagocytosis by neutrophils/macrophages, followed by resolution mechanisms that restore homeostasis. Key molecular players include epidermal growth factor receptor (EGFR), mitogen activated protein kinases like ERK1/2 which regulate keratinocyte responses to pro-inflammatory signals such as TNF-alpha or IFN-gamma. The acute phase is self-limiting under normal conditions; dysregulation leads to chronic skin diseases. While many drugs modulate this process at various points—such as NSAIDs inhibiting prostaglandin synthesis—there is no singular "receptor" called the "inflammatory response." Therefore this entry should be considered incorrect for structured drug-target mapping purposes.[1][2][3][4]

Other names

Inflammatory response in skinEpidermal inflammationCutaneous inflammatory response

NSAIDs inhibit cyclooxygenase enzymes to reduce prostaglandin synthesis and thus inflammation and pain in tissue injury; other anti-inflammatory agents may block cytokines or chemokines involved in the process[3].